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Abstract 
Extracorporeal membrane oxygenation (ECMO) is an aggressive life support technique that utilizes extracorporeal 
circuits and oxygenators to support severe lung injury such as acute respiratory distress syndrome (ARDS), as well 
as severe cardiac disorders like cardiogenic shock and cardiac arrest.  Veno-Venous (VV) ECMO is primarily used 
in respiratory distress.  Clots can form within the oxygenator or circuit, which can develop embolic complications or 
flow problems. To prevent this, patients are anticoagulated, usually with heparin.  However patients can develop 
bleeding complications, and therefore must have their AC discontinued.  A retrospective chart review was done on 
57 VV ECMO patients, out of which 19 had their heparin held for at least one period of 24 hours or longer.  
Temporarily non-heparinized patients required far more oxygenator and circuit replacements than control (58% 
compared to 8% of patients), had more DVTs (37% compared to 21%), and had a higher mortality rate (47% 
compared to 29%), however the rates of DVT per day on ECMO were very similar.   Patients in the non-heparinized 
cohort died when the families withdrew care because of prolonged ECMO without improvement, worsening sepsis, 
and/or severe bleeding complications.   Based on these findings there is no direct evidence that temporarily 
discontinuing AC resulted in increased patient mortality.  This was more likely due to increased severity of illness 
and bleeding complications, evidenced by the increased time on ECMO. 
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Introduction 
Extracorporeal membrane oxygenation (ECMO), also 
known as extracorporeal life support (ECLS) is a very 
aggressive technique that utilizes extracorporeal circuits 
and oxygenators to support severe lung injury such as 
acute respiratory distress syndrome (ARDS), as well as 
cardiac support for cardiogenic shock and cardiac 
arrest.  There are two major categories of ECMO:  
Veno-Venous ECMO is primarily used in respiratory 
distress, using a right internal jugular vein access; and 
Veno-Arterial ECMO is primarily used for cardiac or 
cardiopulmonary support, using femoral vein and artery 
access
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.  Extra Corporeal Life Support (ECLS) is 
sometimes used synonymously.  
Blood that comes into contact with foreign surfaces 
tends to coagulate. Clots that form within the 
oxygenator and extracorporeal tubing can be pushed 
into the patient and ultimately cause a thrombus, or in 
severe cases, a stroke. Therefore, as part of the protocol 
for extracorporeal circuits, patients undergo 
anticoagulation (AC) therapy and are uniformly 
heparinized with a partial thromboplastin time (PTT) in 
the range of 50-70 seconds, and an activated clotting 
time (ACT) of 180-200 sec
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.  
Some of these severely ill patients can develop bleeding 
complications involving the oral pharyngeal cavity, 
abdominal cavity, thoracic cavity, and cannulation sites.  
In these cases, because of ongoing bleeding and 
exploratory surgery, AC needs to be stopped, 
sometimes for prolonged periods of time.  Other 
patients are coagulopathic due to their illness, and 
therefore don’t receive therapeutic AC. 
Major bleeding is defined as clinically overt bleeding 
associated with a hemoglobin (Hgb) fall of at least 2 
g/dl in a 24 hour period, greater than 20 ml/kg over a 24 
hour period, or a transfusion requirement of one or 
more 10 ml/kg packed red blood cell (PRBC) 
transfusions over that same time period. In addition, 
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bleeding that is retroperitoneal, pulmonary or involves 
the central nervous system, or bleeding that requires 
surgical intervention would also be considered major 
bleeding. Minor bleeding would be considered less than 
20 ml/kg/day and require transfusion of one 10 ml/kg 
PRBC transfusion, or less. This is significant, because 
hemorrhagic complications and the requirement for 
greater red blood cell transfusion volumes are 




The ultimate goal of this project was to review the 
safety and outcome of patients on ECMO in whom 
therapeutic anticoagulation is held secondary to 
bleeding complications, as there is no significant body 
of literature regarding this topic. 
Methods 
This retrospective study involved 57 VV ECMO 
patients (47% male, average age:  48) selected from the 
hospital database.   Patients were sorted based off of the 
following inclusion criteria: (1) Patient had to have 
been on VV ECMO at LVHN since 2013, and (2) 
Patient had to be at least 18 years old.  Of the 57 
patients, 19 had their heparin held for at least one 
period of 24 hours or longer.  All patients’ electronic 
medical records (EHMR) were examined to determine 
incidence of upper extremity (UE) and lower extremity 
(LE) deep vein thrombosis (DVT), patient mortality, 
and possible link between thrombotic complications 
and patient outcomes.  Thrombotic complications 
include stroke, ischemic limb, kidney and liver injury, 
and surgical procedures for bleeding from body cavities 
and insertion sites.  Records were also examined to 
determine if/how many oxygenator or circuit changes 
were necessary.  For patients whose heparin was held, 
the source of bleeding was determined. 
Incidence of DVT, as well as need for 
oxygenator/circuit changes were calculated both as a 
percentage of the population, and as a rate of total 
events per total days on ECMO for that group. This was 
done in an attempt to normalize the data to account for 
the large difference between groups in average time 




The 19 patients whose heparin was held for a period of 
at least 24 hours (non-heparinized patients) spent an 
average of 25 days on ECMO, with an average AC hold 
time of 175 hours, while the 38 control patients spent 
an average of 10 days on ECMO (Table 1).  The non-
heparinized group was 47% male, with an average age 
of 46, and the control group was 42% male with an 
average age of 49 (Table 1). 
58% of non-heparinized patients required oxygenator or 
circuit changes, at a rate of 0.034 changes per total day 
on ECMO (16 changes/475 days), while only 7.8% of 
control patients required changes, at a rate of 0.0079 (3 
changes/379 days) (Table 1).  26% of non-heparinized 
patients and 13% of control patients experienced a LE 
DVT, but the rates were more similar at 0.017 (8 
DVTs/475 days) and 0.013 (5 DVTs/379 days), 
respectively (Table 1).  This trend continued with UE 
DVTs; although 26% of non-heparinized patients 
experienced an UE DVT compared to 11% of control 
patients, non-heparinized patients’ rate of 0.017 (8 
DVTs/475 days) was actually lower than control 
patients’ rate of 0.026 (10 DVTs/379 days) (Table 1). 
The mortality rate for non-heparinized patients was 
47% (9/19), with 6 out of 9 patients’ families deciding 
to withdraw care.  The mortality rate for control 
patients was 29% (11/38), with 7 out of 11 patients’ 
families deciding to withdraw care (Table 1). 11% 
(2/19) of non-heparinized patients were discharged 
home and 42% (8/19) were discharged to rehab 
facilities, while 18% (7/38) of control patients were 
discharged home and 55% (21/38) were discharged to 
rehab facilities (Table 1). 
Reasons for discontinuing heparin or other AC included 
hemoptysis (7/19) and oropharyngeal (5/19), 
tracheotomy site (6/19), and cannula site (6/19) 
bleeding.  VV ECMO patient etiology included H1N1 
(28%), pneumonia (16%), aspiration (14%), Legionella 
(9%), post-operative complications (7%), MI and 
cardiac arrest (5%), and other illnesses (9%).  Etiology 
was unknown for 12% of patients (Figure 3). 
Non-heparinized patients died due to severe bleeding, 
sepsis, hypoxia-related brain death, and family 
withdrawing care due to prolonged ECMO treatment 
without improvement (Table 3). 
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Conclusions 
Patients whose heparin was held for period(s) of at least 
24 hours required oxygenator and circuit changes much 
more frequently.  They also experienced more DVTs 
and had a higher mortality rate; however, their overall 
rate of DVTs per day on ECMO is similar that of the 
control group, indicating that the increased incidence of 
DVT is likely due to the significantly longer average 
amount of time those patients spent on ECMO relative 
to control patients.  Patients in the non-heparinized 
cohort mostly died when the families withdrew care 
because of prolonged ECMO without improvement, 
worsening sepsis, and/or severe bleeding complications.  
There were no obvious systemic thrombotic 
complications.  Based on these findings there is no 
direct evidence that temporarily discontinuing AC 
resulted in increased patient mortality.  This was more 
likely due to increased severity of illness and bleeding 
complications, requiring more time on ECMO. 
The study has quite a few limitations. It cannot 
necessarily be broadly applied due to the small sample 
size of only 57 total patients over three years, with an 
experimental group of only 19 patients.  Furthermore, 
only statistics from a single hospital system were 
examined.  However, the findings indicate that at least 
in this patient cohort, there was no obvious link 
between withholding anticoagulation therapy while on 
ECMO and increased patient mortality.  This suggests 
that in contrast to standard ECMO protocol, it might be 
reasonable to withhold heparin from ECMO patients - 
at least temporarily - in the case of moderate to severe 
bleeding
2
.  Further study is indicated to determine 
whether the results of this study are generalizable to a 
wider patient population, and whether discontinuing 
AC therapy in ECMO patients does in fact affect 
patient mortality. 
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Table 1:  LVHN VV ECMO data 2013-2015  
 













Figure 1:  Etiology of LVHN VV ECMO patients 2013-
2015 
Table 3:  Causes of death for heparin-held patients 
 
Figure 2:  Patient complications and outcomes as 
percentage of total group 
 
Figure 3:  Rate of patient complications (total # of 
events per total days on ECM
 
